NAD+
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
NAD+ is not a peptide. It is a dinucleotide – two nucleosides joined by a phosphate bridge – and it may be the most consequential small molecule in human metabolism. Every cell that generates energy, repairs its genome, or signals its own age does so in part through NAD+. Its concentration is not fixed; it declines measurably with age, caloric excess, and genotoxic stress. Understanding why that decline matters requires tracing the molecule through four distinct biochemical roles, each with its own set of proteins, each with its own claim on longevity.
Redox transfer is the foundational role of NAD⁺ in cellular metabolism. It accepts hydride during glucose, fatty acid, and amino acid catabolism to form NADH, which then donates electrons to Complex I of the mitochondrial electron transport chain.
Sirtuin signaling links NAD⁺ availability to transcriptional control, stress adaptation, and mitochondrial biogenesis. Because SIRT1 through SIRT7 consume NAD⁺ during catalysis, age-related depletion can attenuate this broader regulatory axis.
PARP activity draws directly on NAD⁺ stores during the DNA damage response. PARP1 and PARP2 use NAD⁺ to build poly-ADP-ribose chains at sites of strand breaks, so sustained genotoxic stress can materially deplete cellular pools.
CD38-mediated consumption is a major contributor to age-related NAD⁺ decline. CD38 expression rises with age and chronic inflammation, and experimental inhibition or deletion preserves NAD⁺ availability in preclinical models.
What we observe
Changes people report in energy and focus
The outcomes attributed to NAD⁺ repletion span energy metabolism, DNA repair capacity, cognitive function, and metabolic health markers. What follows reflects patterns reported in peer-reviewed human and animal studies. Individual response varies with baseline NAD⁺ status, age, and route of administration. Aeterna does not prescribe, dispense, or sell.
01
Mitochondrial Biogenesis
02
DNA Repair Capacity
03
Neurological Resilience
04
Metabolic Regulation
05
Inflammatory Modulation
06
Physical Recovery
Evidence
The data behind NAD+
The evidence base for NAD⁺ spans decades of foundational biochemistry and a more recent wave of controlled human supplementation trials. The studies below represent a cross-section of the published record, selected for methodological rigor and clinical relevance. They are presented for educational orientation only. Aeterna does not prescribe, dispense, or sell.
Nicotinamide Riboside Supplementation Alters the Gut Microbiota and Attenuates Systemic Inflammation in Healthy Middle-Aged and Older Adults
A randomized, double-blind, placebo-controlled crossover trial at the University of Colorado Boulder enrolled 24 healthy adults aged 55–79. Six weeks of oral NR supplementation (1,000 mg/day) increased whole-blood NAD+ metabolome by approximately 60% relative to placebo. Systemic inflammatory markers, including circulating IL-6 and TNF-α, were significantly reduced. No serious adverse events were recorded. The authors noted that the magnitude of NAD+ increase correlated with baseline deficiency, suggesting a repletion rather than supraphysiological effect.
Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging
This landmark preclinical study from the Sinclair Laboratory at Harvard Medical School demonstrated that age-related NAD+ decline in mice disrupts the interaction between SIRT1 and HIF-1α, inducing a pseudohypoxic state that impairs mitochondrial homeostasis. Administration of NMN to 22-month-old mice for one week restored NAD+ levels to those of 6-month-old animals and reversed multiple markers of mitochondrial dysfunction. The findings established a mechanistic framework linking NAD+ decline to the mitochondrial hallmarks of aging.
Effect of Nicotinamide Mononucleotide on Muscle Insulin Sensitivity in Prediabetic Women: A Randomized Clinical Trial
A 10-week randomized controlled trial at Washington University School of Medicine in St. Louis enrolled 25 postmenopausal women with prediabetes. Oral NMN (250 mg/day) significantly increased skeletal muscle NAD+ content and improved insulin-stimulated glucose disposal, as measured by hyperinsulinemic-euglycemic clamp. Gene expression analysis revealed upregulation of pathways involved in mitochondrial biogenesis and muscle remodeling. The authors concluded that NMN supplementation can improve muscle insulin sensitivity in this population, though larger trials are required to confirm clinical benefit.
From lyophilized powder to a usable solution.
Peptide
500 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
166.7 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 50–100 mg once daily subcutaneously (gradual titration from lower doses)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: freeze at −20 °C (−4 °F).
- After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 14 days.
- Protect from light and avoid freeze–thaw cycles.
- Avoid repeated freeze-thaw cycles for lyophilized powder; each cycle degrades the dinucleotide structure and reduces potency
- Verify purity via certificate of analysis from supplier; NAD+ is susceptible to oxidation and hydrolysis - degraded product yields NAAD and AMP, which are biologically inert in this context
Side effects
What members describe
- IV infusion: flushing, chest tightness, palpitations, and nausea are common at infusion rates above 2 mg/min; symptoms typically resolve with rate reduction
- IV infusion: transient hypotension and lightheadedness reported, particularly in the first 30 minutes; patient should remain supine during administration
- Oral precursors: mild gastrointestinal discomfort (nausea, loose stool) reported at doses above 1,000 mg/day; generally self-limiting
- Theoretical concern: high-dose NAD+ repletion may increase PARP activity and thereby support survival of pre-neoplastic cells; this hypothesis has not been confirmed in human studies but warrants consideration in oncology contexts
- Flushing and warmth during IV infusion are attributed to prostaglandin release and are not indicative of allergic reaction; distinguish from true anaphylaxis by absence of urticaria and bronchospasm
Contradictions
Reasons to abstain
- Active malignancy: theoretical PARP and sirtuin-mediated cytoprotection may be counterproductive; use only under oncologist guidance
- Severe hypotension or hemodynamic instability: IV administration carries risk of further blood pressure reduction
- Known hypersensitivity to nicotinamide or niacin derivatives: cross-reactivity is plausible; patch testing or graded oral challenge under supervision before IV use
- Pregnancy and lactation: no controlled safety data; endogenous NAD+ is essential for fetal development, but exogenous supraphysiological dosing has not been studied in human pregnancy
- Concurrent use of PARP inhibitors (e.g., olaparib, niraparib) in oncology patients: pharmacodynamic antagonism is theoretically possible; co-administration not studied
Synergies
What works well with NAD+
NAD+ does not operate in isolation. Several compounds studied in the longevity and metabolic literature engage overlapping or complementary pathways – sirtuin activation, mitochondrial biogenesis, senolysis, and redox balance. The pairings below reflect mechanistic rationale drawn from preclinical and early human data. They are not protocols. Aeterna does not prescribe, dispense, or sell.
FAQ
Your questions, patiently answered
No. NAD+ is a dinucleotide coenzyme – a small molecule composed of two nucleosides (adenosine and nicotinamide mononucleotide) linked by a phosphate bridge. It is not a peptide or protein. It is included in the Aeterna curriculum because it occupies a central position in the same longevity and metabolic signaling networks that many studied peptides engage, and because its pharmacology is frequently misunderstood in popular discourse.
Several mechanisms contribute. PARP enzymes consume NAD+ in response to the accumulating DNA damage of aging. CD38 expression increases with age and chronic inflammation, accelerating NAD+ hydrolysis. Biosynthetic capacity from tryptophan and nicotinamide precursors may also decline. The net result is a measurable fall in tissue NAD+ concentrations – documented in human skeletal muscle, liver, and brain – that begins in the fourth decade and accelerates thereafter.
NAD+ is the active coenzyme. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are biosynthetic precursors that the cell converts to NAD+ via distinct enzymatic pathways. Oral NAD+ itself is poorly absorbed intact; precursor forms are more bioavailable by the oral route. IV administration delivers NAD+ directly to the bloodstream, bypassing intestinal absorption, but the molecule’s plasma half-life is very short – cellular uptake and conversion to NADH occur rapidly.
The pharmacokinetic argument for IV administration is that it bypasses intestinal and hepatic first-pass metabolism, delivering a bolus of NAD+ directly to circulation. Whether this translates to meaningfully superior tissue repletion compared to sustained oral precursor dosing is not established in head-to-head human trials. IV administration is associated with a more pronounced acute side-effect profile and requires clinical supervision. The choice between routes should be guided by clinical context, not convenience.
This is a legitimate and unresolved question in the literature. NAD+ is required for PARP-mediated DNA repair – a process that is generally protective – but also supports the metabolic demands of rapidly dividing cells. In vitro and some animal studies suggest that NAD+ repletion can support tumor cell survival under certain conditions. No human study has demonstrated increased cancer incidence with NAD+ precursor supplementation, but the question has not been adequately powered in long-term trials. Individuals with active malignancy or high cancer risk should discuss this consideration with their oncologist before use.
Whole-blood NAD+ metabolomics – measuring NAD+, NADH, NMN, NR, and related metabolites – is the most comprehensive assessment and is available through specialized reference laboratories. Simpler assays measuring NAD+ in peripheral blood mononuclear cells (PBMCs) are used in research settings. No standardized clinical reference range for NAD+ status has been established as of 2025, which limits the utility of testing outside of research protocols.
In the same family
Further reading in the curriculum.
Sourcing · Independently verified
When you're ready, source thoughtfully.